



## IBA Notice of Full Year 2019 Results and Conference Call

*FY19 Results Conference Call to take place on Thursday, 26 March 2020 at 3pm CET*

**Louvain-la-Neuve, Belgium, 5 March 2020** - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it will publish its consolidated results for the full year 2019 on **Thursday, 26 March 2020 at 7am CET**.

### Conference Call Information

In addition to the press release, Olivier Legrain, Chief Executive Officer, and Soumya Chandramouli, Chief Financial Officer, will host a conference call and webcast, conducted in English, to present the full year results, followed by a Q&A session.

This conference call will be held on **Thursday, 26 March 2020 at 3pm CET / 2pm GMT / 10am EDT / 7am PDT** and can be accessed online at:

<http://arkadinemea-events.adobeconnect.com/iba260320/event/registration.html> If you would like to participate in the Q&A, please dial (PIN code 72868170#):

Belgium:	+32 2 403 58 16
UK:	+44 20 71 94 37 59
NL:	+31 207 09 51 19
LU:	+352 2 730 01 63
US:	+1 64 67 22 49 16
FR:	+33 1 72 72 74 03

The presentation will be available on [IBA's investor relations](#) website and on: <https://iba-worldwide.com/content/full-year-2019-results-conference-call> shortly before the call.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

### About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle



accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has the largest number of installed proton therapy systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at [www.iba-worldwide.com](http://www.iba-worldwide.com)

### **For further information, please contact:**

#### **IBA**

#### **Soumya Chandramouli**

Chief Financial Officer

+32 10 47 58 90

[Investorrelations@iba-group.com](mailto:Investorrelations@iba-group.com)

#### **Thomas Ralet**

Vice-President Corporate Communication

+32 10 47 58 90

[communication@iba-group.com](mailto:communication@iba-group.com)

### **For media and investor enquiries:**

#### **Consilium Strategic Communications**

Amber Fennell, Angela Gray, Lizzie Seeley

+44 (0) 20 3709 5700

[IBA@consilium-comms.com](mailto:IBA@consilium-comms.com)